Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Advanced melanoma (unresectable stage III and stage IV), drawn from the whole corpus: 60 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
About four in ten patients never respond to PD-1 blockade and no biomarker reliably identifies them.
Who needs the ipilimumab component and its toxicity, and whether relatlimab can replace it, has not been settled.
Nothing recorded yet.
Background: Immune-related adverse events (irAEs). Also on OnCo: Side effects by symptom · Immune-related side effects · Toxicity compare · Survivorship planner.
Acral, mucosal and uveal melanomas respond far less well and have few dedicated trials.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 35 changes by month →When this page itself was last checked or edited.
Accelerated approval with nivolumab for unresectable/metastatic melanoma after anti-PD-1 (IGNYTE)
Unresectable/metastatic melanoma after anti-PD-1, with nivolumab (accelerated)
Primary PFS endpoint not met; numerical +5.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.